SCHEMBL410770

SCHEMBL410770

OC(CNCc1ccccc1)Cn1c2ccccc2c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 17/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896218 0.84 DNM1 (0.73) DNM1
SCHEMBL5307308 0.84 DNM1 (0.73) DNM1
SCHEMBL28406118 0.83 DNM1 (0.88) DNM1
SCHEMBL12858681 0.80 DNM1 (0.67) DNM1
SCHEMBL15380477 0.79 LMNA (1.00) DNM1
SCHEMBL17138489 0.79 DNM1 (0.65) DNM1
SCHEMBL13780682 0.78 DNM1 (0.64) DNM1
SCHEMBL408965 0.78 DNM1 (1.00) DNM1
SCHEMBL14889275 0.78 BACE1 (1.00) DNM1
SCHEMBL893963 0.78 BCHE (0.63) DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
WO-2014031125-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-02-27 WO claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
CN-102405043-A Proneurogenic compounds UNIV TEXAS SOUTHWESTERN MED CT 2012-04-04 CN claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX DNM1 897/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 625/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 510/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX DNM1 897/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF DNM1 538/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF DNM1 510/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 DNM1 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.